Tilray goes global with Novartis marijuana sales partnership

Tilray and Sandoz Canada have been working together since March, when they announced an alliance to develop new medical cannabis products and collaborate on research and education
Swissinfo (Switzerland)
Tuesday, December 18, 2018

Tilray Inc. has signed a global partnership with a division of Swiss drug giant Novartis AG to develop and distribute its medical marijuana in legal jurisdictions around the world. The Canadian pot firm said Tuesday it’s reached an agreement with Sandoz AG to boost the availability of medical cannabis products globally, building on an existing alliance with Sandoz Canada Inc. The two companies will work together to commercialize Tilray’s non-smokable medical marijuana offerings, co-brand certain products, develop new products and educate pharmacists and physicians about pot.